Drug news
Roche acquires rights to POL 7080 for Pseudomonas aeruginosa
Roche and Polyphor Ltd., a privately held pharmaceutical company, announced that they have entered into an exclusive worldwide license agreement for Roche to develop and commercialise Polyphor's investigational macrocycle antibiotic, POL 7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa. The drug is in Phase II trials.